TNFAIP3 and COVID-19: These pieces of evidence suggest that A20 might contribute to hindering the antiviral response in SARS‐CoV‐2 infection and exacerbating respiratory symptoms, further indicating that A20 could be a potential therapeutic target in COVID‐19.